Dr. Reddy's Laboratories Limited

BSE:500124 Voorraadrapport

Marktkapitalisatie: ₹977.9b

Dr. Reddy's Laboratories Toekomstige groei

Future criteriumcontroles 2/6

Dr. Reddy's Laboratories zal naar verwachting groeien in winst en omzet met respectievelijk 17.1% en 8.9% per jaar. De winst per aandeel zal naar verwachting groeien met 20.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.5% zijn.

Belangrijke informatie

17.1%

Groei van de winst

20.58%

Groei van de winst per aandeel

Pharmaceuticals winstgroei17.4%
Inkomstengroei8.9%
Toekomstig rendement op eigen vermogen11.47%
Dekking van analisten

Good

Laatst bijgewerkt02 Aug 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • Jul 23

500124: New Biologics And Diabetes Launches Will Drive Future Upside

Analysts have trimmed their price target on Dr. Reddy's Laboratories from ₹1,679 to about ₹1,600, citing updated assumptions that combine slightly higher projected revenue growth and profit margins with a lower future P/E multiple. What's in the News Dr. Reddy's Laboratories reported that the USFDA completed a Pre License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad, issuing a Form 483 with seven observations that the company plans to address within the required timeline.
Narratiefupdate • Jun 25

500124: Lower Profitability Expectations Will Restrain Future Share Price Upside

Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.
Narratiefupdate • Jun 05

500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes

Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.
Narratiefupdate • May 22

500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments

Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.
Narratiefupdate • May 03

500124: Future Tax Compliance And Regulatory Setbacks Will Curb Share Price Upside

Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,024, explaining that small adjustments to revenue growth, profit margin and future P/E assumptions did not materially change their overall price target view. What's in the News Health Canada granted Dr. Reddy's a Notice of Compliance for its generic Semaglutide Injection, allowing commercialization and sale in Canada.
Narratiefupdate • Apr 19

500124: Future Tax And Regulatory Compliance Issues Will Limit Upside Potential

Analysts have revised their price target for Dr. Reddy's Laboratories to ₹1,024, reflecting updated assumptions of higher revenue growth of 5.96%, a profit margin of 16.95% and a lower future P/E of 17.43x. What's in the News Launch of Obeda, an injectable semaglutide for type 2 diabetes in India, following Drugs Controller General of India approval for generic semaglutide.
Narratiefupdate • Apr 05

500124: Fair Outlook Will Balance Biosimilar Opportunity And Compliance Developments

Analysts have increased their price target on Dr. Reddy's Laboratories by about ₹13 to ₹1,314, citing updated assumptions that include a different discount rate, revised revenue growth and profit margin estimates, and an adjusted future P/E multiple. What's in the News Board meeting scheduled for March 24, 2026, to amend the Code of Practices and Procedures for Fair Disclosures of Un published Price Sensitive Information, signaling a focus on disclosure norms and compliance (company filing).
Narratiefupdate • Mar 21

500124: Biosimilar Pipeline Progress Will Drive Future Upside Despite GST Disputes

Analysts have maintained their price target for Dr. Reddy's Laboratories at ₹1,615. This reflects only minor adjustments to revenue growth, profit margin and forward P/E assumptions, rather than a change in the overall valuation view.
Narratiefupdate • Mar 07

500124: Biosimilar Approvals Will Drive Future Upside Despite Regulatory And Tax Overhang

Analysts have kept their price target for Dr. Reddy's Laboratories unchanged at ₹1,615, citing only marginal tweaks to revenue growth, profit margin and forward P/E assumptions that do not materially alter their valuation view. What's in the News The USFDA has accepted review of Dr. Reddy's 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to ORENCIA (abatacept) for multiple autoimmune indications, supported by analytical, PK and clinical data, including an ongoing Phase 3 trial (company announcement).
Narratiefupdate • Feb 21

500124: Biosimilar Pipeline And New Launches Will Drive Future Upside

Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories slightly higher from about ₹1,611 to roughly ₹1,615 per share, reflecting updated assumptions on revenue growth, profit margins, and the future P/E multiple in their models. What's in the News US FDA accepted review of a 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to Orencia (abatacept), for multiple rheumatoid and arthritis indications in adults and children, backed by analytical, PK, and clinical data including Phase 1 PK similarity and an ongoing Phase 3 trial (company announcement).
Narratiefupdate • Feb 07

500124: Future Regulatory And Tax Compliance Risks Will Limit Upside Potential

Analysts have raised their fair value estimate for Dr. Reddy's Laboratories from ₹990 to ₹1,024, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E as key drivers of this change. What's in the News Launched OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent to Extra Strength Pataday Once Daily Relief, for temporary relief of itchy eyes caused by allergens.
Narratiefupdate • Jan 23

500124: Biosimilar Approvals And New Launches Will Drive Future Upside

Analysts have trimmed their price target on Dr. Reddy's Laboratories slightly from ₹1,615 to about ₹1,611, reflecting updated views on future revenue growth, profit margins, and a higher assumed future P/E multiple. What's in the News Launched an over the counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent of Extra strength Pataday Once Daily Relief, targeting temporary relief of itchy eyes from allergens such as pollen, grass and animal dander (USFDA approval).
Narratiefupdate • Jan 06

500124: Biosimilar Approvals Will Support Future Upside As Regulatory Issues Remain Contained

Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,615, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions that they view as offsetting each other. What's in the News Dr. Reddy's received five separate orders from the GST Authority for tax demand, interest, and penalties related to alleged excess input tax credit for FY2018-19 to FY2022-23, with penalties of ₹1,89,30,110, ₹80,41,186, ₹3,52,95,063, ₹1,45,04,023 and ₹70,86,675 respectively.
Narratiefupdate • Dec 14

500124: Biosimilar Approvals Will Drive Future Upside Despite Slight Multiple Compression

Analysts have marginally lowered their price target on Dr. Reddy's Laboratories to ₹1,615 from ₹1,626, reflecting a slightly higher discount rate, while also factoring in stronger revenue growth, improved profit margins and a somewhat lower future P E multiple. What's in the News European Commission grants marketing authorization for AVT03, Dr. Reddy's and Alvotech's biosimilar to Prolia and Xgeva, with Dr. Reddy's holding exclusive commercialization rights in the U.S. and semi exclusive rights in Europe and the UK (company announcement) EMA's CHMP earlier issued a positive opinion recommending AVT03 for marketing authorization across the European Economic Area, with a separate submission planned to the UK MHRA under the International Recognition Procedure (company announcement) Dr. Reddy's receives an Establishment Inspection Report from the USFDA, with the inspection classified as Voluntary Action Indicated and officially closed (regulatory filing) Eisai and Dr. Reddy's reach a patent settlement allowing Dr. Reddy's to launch a generic version of cancer drug Lenvima in the U.S. from July 1, 2030, subject to certain contingencies (legal filing) Company launches Tegoprazan in India under the brand name PCAB to treat acid related gastrointestinal diseases, targeting a large and growing acid peptic disease population (product launch) Valuation Changes The fair value estimate has been reduced slightly to ₹1,615 from ₹1,625.93, reflecting a modestly more conservative outlook.
Narratiefupdate • Oct 27

Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities

Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.
Narratiefupdate • Sep 04

Investments In Biosimilars And NRT Will Expand Market Reach, Yet Regulatory Hurdles May Persist

With both revenue growth and net profit margin forecasts steady, analysts maintained their fair value estimate for Dr. Reddy's Laboratories at ₹1287. What's in the News Dr. Reddy's Laboratories and Extrovis AG launched Fluorouracil Cream, 0.5% in the US as an authorized generic, approved by the USFDA.
User avatar
Nieuw narratief • Nov 13

Regulatory Hurdles And Rising Expenses Threaten To Squeeze Margins And Stifle Growth

Upfront costs from acquisitions and partnerships may pressure short-term earnings and compress net margins.

Winst- en omzetgroeiprognoses

BSE:500124 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/2029432,81357,71648,23870,23820
3/31/2028392,78048,98936,28256,30337
3/31/2027351,91337,22139,64858,98837
6/30/2026331,18633,10712,73541,199N/A
3/31/2026335,93342,85019,73156,755N/A
12/31/2025345,83156,58724,95263,106N/A
9/30/2025342,14958,62219,02358,818N/A
6/30/2025334,26056,80215,17252,561N/A
3/31/2025325,53556,54412,76246,428N/A
12/31/2024311,30553,6766,93635,952N/A
9/30/2024299,86753,3328,83034,069N/A
6/30/2024288,50755,57921,01242,679N/A
3/31/2024279,16455,68418,01945,433N/A
12/31/2023271,30252,20628,71353,592N/A
9/30/2023266,85450,88849,17972,115N/A
6/30/2023261,10947,21641,12363,470N/A
3/31/2023245,87945,06740,00958,875N/A
12/31/2022237,27936,35029,17048,315N/A
9/30/2022222,77630,94421,86642,386N/A
6/30/2022217,35129,73616,75538,211N/A
3/31/2022214,39123,56812,00528,108N/A
12/31/2021207,30726,31714,97630,255N/A
9/30/2021203,40619,4501,59717,194N/A
6/30/2021194,74117,1537,33521,342N/A
3/31/2021189,72217,23823,14235,703N/A
12/31/2020186,75621,25615,52826,983N/A
9/30/2020181,29815,36122,02630,069N/A
6/30/2020180,34018,66324,35430,921N/A
3/31/2020174,60019,498N/A29,841N/A
12/31/2019170,44816,200N/A34,006N/A
9/30/2019165,11026,749N/A42,937N/A
6/30/2019155,07920,862N/A43,559N/A
3/31/2019153,85118,795N/A28,704N/A
12/31/2018149,03417,473N/A27,774N/A
9/30/2018148,59415,965N/A19,007N/A
6/30/2018145,90313,776N/A14,986N/A
3/31/2018141,8559,806N/A18,029N/A
12/31/2017141,8279,909N/A20,765N/A
9/30/2017140,58811,266N/A18,478N/A
6/30/2017140,90711,367N/A14,480N/A
3/31/2017139,87012,039N/A21,513N/A
12/31/2016141,2699,660N/A22,252N/A
9/30/2016144,12710,751N/A29,018N/A
6/30/2016148,41015,019N/A37,693N/A
3/31/2016153,86620,013N/A41,247N/A
12/31/2015155,85024,456N/A42,252N/A
9/30/2015154,60224,409N/A36,012N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 500124 ( 17.1% per jaar) ligt boven de spaarquote ( 6.9% ).

Winst versus markt: De winst van 500124 ( 17.1% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 16.4% per jaar).

Hoge groeiwinsten: De winst van 500124 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 500124 ( 8.9% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 11% per jaar).

Hoge groei-inkomsten: De omzet van 500124 ( 8.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 500124 zal naar verwachting over 3 jaar laag zijn ( 11.5 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/08/05 22:12
Aandelenkoers aan het einde van de dag2026/08/05 00:00
Inkomsten2026/06/30
Jaarlijkse inkomsten2026/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Dr. Reddy's Laboratories Limited wordt gevolgd door 74 analisten. 38 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Rohit Bhat360 ONE Capital Market Private Limited
Gaurav TinaniAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited